Eisai Plans $80 Million Investment In U.S. Antibody Production
This article was originally published in PharmAsia News
Executive Summary
Eisai's plans to establish a major presence in the United States to develop and market antibody drugs is going to cost the company about $80 million. Part of the funds is to go to building a facility next to its Morphoteck subsidiary in Pennsylvania. Construction is to begin next spring, with the plant coming on-line in fiscal 2012. At first, the plant is to be used to produce antibody drugs for clinical trials, but would upgrade the facility for mass production if needed. (Click here for more - a subscription may be required